Literature DB >> 26072064

Crosstalk between peroxisome proliferator-activated receptor-γ and mineralcorticoid receptor in TNF-α activated renal tubular cell.

Jing Xiao1, Weijun Chen, Yijun Lu, Xiaoli Zhang, Chensheng Fu, Zhenwen Yan, Zhenxing Zhang, Zhibin Ye.   

Abstract

INTRODUCTION: In our previous study, we observed the crosstalk between peroxisome proliferator-activated receptor-γ (PPAR-γ) and angiotensin II in activated renal tubular cells. The present study is aimed to further explore the crosstalk between PPAR-γ and mineralocorticoid receptor (MR) in tumor necrosis factor (TNF)-α activated renal tubular cells.
METHODS: Human proximal renal tubular epithelial cells HK-2 were cultured with the pre-treatment of PPAR-γ agonist, pioglitazone (5 μM), MR antagonist, eplerenone (5 μM), or their combined treatment, followed by activation with TNF-α (20 ng/ml). In the parallel experiment, PPAR-γ inhibitor GW9662 (25 µM) was used to study the independence of PPAR-γ. Gene expression and protein synthesis of intercellular adhesion molecule-1 (ICAM-1), interleukin-6 (IL-6), MR and PPAR-γ were measured by RT-PCR, ELISA and Western blot, respectively; nuclear factor κB (NF-κB) nuclear translocation activity in the nucleus was examined by EMSA assay.
RESULTS: TNF-α effectively activated HK-2 cells by up-regulating gene expression and protein synthesis of ICAM-1, IL-6 and MR and down-regulating PPAR-γ in a dose-dependent manner. TNF-α also significantly induced NF-κB nuclear translocation in HK-2 cells. Dual treatment of pioglitazone and eplerenone demonstrated synergistic effect on reducing ICAM-1 and IL-6 expression and alleviating NF-κB activation when compared with their monotherapies in TNF-α activated renal tubular cells. PPAR-γ antagonist, GW9662, significantly attenuated protective effect on ICAM-1, IL-6 and PPAR-γ expression by pioglitazone, eplerenone and their combined treatment.
CONCLUSIONS: Our data suggest that pioglitazone, in a PPAR-γ-dependent manner, trans-represses MR signaling by suppressing NF-κB activation. MR antagonist also restored PPAR-γ expression. Dual treatment of pioglitazone and eplerenone present better efficacy in attenuating excessive inflammatory response in activated renal tubular cells under stimulation of TNF-α than single treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26072064     DOI: 10.1007/s00011-015-0838-5

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  37 in total

1.  Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes.

Authors:  Chin-Feng Tsai; Shun-Fa Yang; Hsiao-Ju Chu; Kwo-Chang Ueng
Journal:  Int J Cardiol       Date:  2013-10-08       Impact factor: 4.164

2.  Aldosterone inhibits endothelial morphogenesis and angiogenesis through the downregulation of vascular endothelial growth factor receptor-2 expression subsequent to peroxisome proliferator-activated receptor gamma.

Authors:  Miki Fujii; Isao Inoki; Makoto Saga; Norihiro Morikawa; Ken-ichiro Arakawa; Satoru Inaba; Kazuaki Yoshioka; Tadashi Konoshita; Isamu Miyamori
Journal:  J Steroid Biochem Mol Biol       Date:  2011-12-28       Impact factor: 4.292

3.  Opposite action of peroxisome proliferator-activated receptor-gamma in regulating renal inflammation: functional switch by its ligand.

Authors:  Xiaoyan Wen; Yingjian Li; Youhua Liu
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

Review 4.  Aspects of immune dysfunction in end-stage renal disease.

Authors:  Sawako Kato; Michal Chmielewski; Hirokazu Honda; Roberto Pecoits-Filho; Seiichi Matsuo; Yukio Yuzawa; Anders Tranaeus; Peter Stenvinkel; Bengt Lindholm
Journal:  Clin J Am Soc Nephrol       Date:  2008-08-13       Impact factor: 8.237

5.  Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines.

Authors:  Christine Guo; Vincent Ricchiuti; Bill Q Lian; Tham M Yao; Patricia Coutinho; José R Romero; Jianmin Li; Gordon H Williams; Gail K Adler
Journal:  Circulation       Date:  2008-04-21       Impact factor: 29.690

Review 6.  Immunoregulatory role of TNFalpha in inflammatory kidney diseases.

Authors:  Thomas Ernandez; Tanya N Mayadas
Journal:  Kidney Int       Date:  2009-05-13       Impact factor: 10.612

7.  Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.

Authors:  Vasantha Kolavennu; Lixia Zeng; Hui Peng; Yin Wang; Farhad R Danesh
Journal:  Diabetes       Date:  2007-12-14       Impact factor: 9.461

8.  Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.

Authors:  James M Luther; Pengcheng Luo; Zuofei Wang; Samuel E Cohen; Hyung-Suk Kim; Agnes B Fogo; Nancy J Brown
Journal:  Kidney Int       Date:  2012-05-23       Impact factor: 10.612

9.  Effect of eplerenone, a selective aldosterone blocker, on the development of diabetic nephropathy in type 2 diabetic rats.

Authors:  Jae Hee Ahn; Ho Cheol Hong; Myong Jin Cho; Yoon Jung Kim; Hae Yoon Choi; Chai Ryoung Eun; Sae Jeong Yang; Hye Jin Yoo; Hee Young Kim; Ji A Seo; Sin Gon Kim; Kyung Mook Choi; Sei Hyun Baik; Dong Seop Choi; Nan Hee Kim
Journal:  Diabetes Metab J       Date:  2012-04-17       Impact factor: 5.376

Review 10.  NF-kappaB signalling in chronic kidney disease.

Authors:  Gopala Rangan; Yiping Wang; David Harris
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  2 in total

1.  PPARγ regulates inflammatory reaction by inhibiting the MAPK/NF-κB pathway in C2C12 skeletal muscle cells.

Authors:  Jeong-Seok Kim; Young-Hee Lee; Yong-Uoo Chang; Ho-Keun Yi
Journal:  J Physiol Biochem       Date:  2016-10-07       Impact factor: 4.158

2.  Emodin Attenuated the Kidney Damage of High-Fat-Diet Mice via the Upregulation of Glucagon-Like Peptide-1 Receptor.

Authors:  Jinlei Liu; Yao Sun; Hongwei Zheng; Jing Wang; Lili Liu; Bing Song; Haoqiang Zhang
Journal:  Biomed Res Int       Date:  2021-05-31       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.